NEWS

 

Title Date
The mechanism of action and Phase 3 MRCT results of the diabetic foot ulcer new drug, Fespixon have been accepted for an oral presentation at IDF Congress 2021 2021-12-03
Oneness Biotech Co., Ltd. receives a Taiwan patent O titled "TOPICAL FORMULATION FOR PROMOTING WOUND HEALING" O on Fespixon cream (Research code: ON101). 2021-12-02
Oneness Biotech and Tanner Pharma Group initiate early access program for Fespixon®, a novel macrophage-regulating new therapy for the treatment of diabetic foot ulcers 2021-11-15
News-Diabetes Self-Management:New Cream Cures Foot Ulcers 2021-11-12
Oneness Biotech Co., LTD. receives a Mexican patent titled "TOPICAL FORMULATION FOR PROMOTING WOUND HEALING" on Fespixon cream (Research code: ON101). 2021-10-22
An Australian patent on the producing of recombinant glycoproteins with modified glycosylation was granted. 2021-10-19
News-Press Release of The Publication the Ph3 Data And The Mechanism of Action of Fespixon（ON101）on JAMA Network Open 2021-10-18
A Malaysian patent on the Anti-CεMx (FB825) antibody was granted. 2021-10-13
Oneness has been notified by the US FDA on the acceptance of ON101 medical device 510(k) application 2021-10-12
The Board of Directors of Oneness has approved a donation to Teh-Tzer Study Group for Human Medical Research Foundation. 2021-10-08
Oneness Biotech has been invited to present at the "10th Taiwan CEO Week on Air" online investor’s conference co-organized by TWSE and QIC. 2021-10-08
Oneness announces the information about the investor's conference of 2021 Q3. 2021-09-15
A Hong Kong patent titled "USE OF PATCHOULI EXTRACT IN THE PREPARATION OF COMPOSITIONS WITH AN ANTI-MICROORGANISM EFFECT" has been granted. 2021-09-14
News-Medscape：Novel Diabetic Foot Ulcer Cream Shows Promise in Phase 3 Trial 2021-09-11
The data of the Phase 3 international multicenter clinical trial and the mechanism of action of Fespixon (ON101) have been published by JAMA Network Open 2021-09-04
Oneness decided not to proceed with FB704A phase 2 IND application in patients with severe COVID-19 based on strategic consideration 2021-09-04
Oneness Biotech Co., LTD receives a Japanese patent on OB318, a new drug in development for liver cancer. 2021-09-02
Oneness Biotech Co., LTD receives a Chinese patent on OB318, a new drug in development for liver cancer. 2021-08-10
A Chinese patent on the producing of recombinant glycoproteins with modified glycosylation was granted. 2021-08-09
Oneness Biotech Co., LTD. receives a Russian patent titled"TOPICAL FORMULATION FOR PROMOTING WOUND HEALING" on Fespixon cream (Research code:ON101). 2021-07-21